Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium; Department of Infectious Diseases and Immunity, Jessa Hospital, Hasselt, Belgium; Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Emergency Department, Jessa Hospital, Hasselt, Belgium.
Int J Antimicrob Agents. 2021 Sep;58(3):106379. doi: 10.1016/j.ijantimicag.2021.106379. Epub 2021 Jun 20.
To perform an audit of empirical antibiotic therapy (EAT) of sepsis at the emergency department and to analyse the impact of an antimicrobial stewardship (AMS) programme on process and patient outcomes.
A prospective, single-centre cohort study including patients with sequential organ failure assessment (SOFA) score ≥2 from whom blood cultures were taken was conducted between February 2019 and April 2020. EAT was assessed using eight applicable inpatient quality indicators (IQIs) for responsible antibiotic use. Patient outcomes were hospital length-of-stay (LOS), ICU admission, ICU LOS, and in-hospital mortality.
The audit included 900 sepsis episodes in 803 patients. Full guideline adherence regarding choice and dosing was 45.9%; adherence regarding choice alone was 68.1%. EAT was active against all likely pathogens in 665/787 (84.5%) episodes. In the guideline non-adherent group, choice of EAT was inappropriate in 122/251 (48.6%) episodes. Changes within 3 days occurred in 335/900 (37.2%) episodes. Treating physicians changed administration route more often, whereas microbiological/infectious disease (ID)/AMS consultant advice resulted in de-escalation and discontinuation (P = 0.000). Guideline-adherent choice was associated with significantly shorter LOS (6 (4-11) vs. 8 (5-15) days). Full adherence was associated with significantly lower mortality (23 (6.4%) vs. 48 (11.3%)) and shorter LOS (6 (4-10) vs. 8 (5-14) days).
Five global quality indicators of EAT were measurable in routine clinical practice. Full adherence to guidelines was only moderate. Adherence to guidelines was associated with better patient outcomes.
对急诊科脓毒症的经验性抗生素治疗(EAT)进行审核,并分析抗菌药物管理(AMS)方案对治疗过程和患者结局的影响。
这是一项前瞻性、单中心队列研究,纳入了 2019 年 2 月至 2020 年 4 月间连续器官衰竭评估(SOFA)评分≥2 分并采集血培养的患者。采用 8 项适用于住院患者的抗生素合理使用质量指标(IQI)来评估 EAT。患者结局包括住院时间(LOS)、入住 ICU、ICU LOS 和院内死亡率。
该审核纳入了 803 例患者的 900 例脓毒症发作。在选择和剂量方面完全遵循指南的比例为 45.9%;仅在选择方面遵循指南的比例为 68.1%。在 787 例可能病原体阳性的发作中,EAT 治疗具有针对性且合理的比例为 665/787(84.5%)。在不遵循指南的组中,EAT 选择不当的比例为 122/251(48.6%)。3 天内发生改变的比例为 335/900(37.2%)。治疗医生更常改变给药途径,而微生物学/感染病学(ID)/AMS 顾问的建议则导致降级和停药(P=0.000)。遵循指南的选择与 LOS 显著缩短相关(6(4-11)vs. 8(5-15)天)。完全遵循指南与死亡率显著降低(23(6.4%)vs. 48(11.3%))和 LOS 缩短相关(6(4-10)vs. 8(5-14)天)。
在常规临床实践中可以衡量 EAT 的 5 项全球质量指标。完全遵循指南的比例仅为中等。遵循指南与患者结局改善相关。